This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
One of the portfolio firms of San Diego-based venture capital firm EnterprisePartners , Complete Genomics is set to debut on the market Thursday, after pricing its IPO this evening. Complete Genomics will trade on the NASDAQ Global Market as GNOM. EnterprisePartners owns about 14.8
The company said it is looking to raise up to $86.25M in an offering on the NASDAQ Global Market, trading under the symbol CLDN. Celladon is backed by EnterprisePartners, Pfizer, Lundbeckfond, Novartis Bioventures, J&J Development, GBS Bioventures, MPM Capital, Venrock, H&Q, as well as others.
The firm said the expansion financing would go towards product development and further market expansion. The firm did not say if prior investors EnterprisePartners, RBA No. 5, or Evergreen Venture Partners participated in this round. Bass Associates. READ MORE>>.
San Diego-based XIFIN , a developer of cloud-based software for the healthcare diagnostics market, has been acquired by private equity investor GTCR. XIFIN supplies its software in the molecular diagnostics, pain management/toxicology, anatomic pathology, radiology, hospital outreach, medical device and clinical laboratory markets.
ParAccel said the funding will go towards product development, sales and marketing, and to ramp up services and support. Notably missing from this venture round for the firm was EnterprisePartners, an early backer of the firm. Jarve has joined the board with the funding.
Xirrus said it has launched a channel partner program specifically aimed value added resellers and systems integrators in Europe, as it looks to tackle that new market. Concurrently, the firm said it launched a new enterprisepartner program in the U.S.,
Inphi joins such firms as Green Dot , RealD , ReachLocal , and MaxLinear who have reached the markets so far this year. Complete Genomics, a Silicon Valley firm backed by Southern California venture firm EnterprisePartners, is also expected to debut this week.
The funding was led by JMI Equity, and also included Health EnterprisePartners (HEP) and Health Velocity Capital (HVC). Jvion said it will use the funding to accelerate expansion across its market. Jvion is based in Atlanta, Georgia, and was founded in 2011. READ MORE>>.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content